Companies › Precision BioSciences
2 active drug programs in 2 registered trials: 2 Phase 1; Psychiatry, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PBGENE-HBV In vivo gene editing via ARCUS platform targeting HBV cccDNA and integrated HBV DNA | – | Phase 1 | HEPATITIS B CHRONIC | Dec 2026 |
| PBGENE-DMD Ex vivo gene editing therapy targeting DMD mutations amenable to exons 45-55 excision | DMD | Phase 1 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | Nov 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06680232 | PBGENE-HBV | Phase 1 | HEPATITIS B CHRONIC | Infectious disease | Dec 2026 |
| NCT07429240 | PBGENE-DMD | Phase 1 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | Psychiatry | Nov 2029 |
Cash and short-term investments of $82m on 2026-09-30; operating cash outflow about $54m a year; runway about 18 months at that burn, to Apr 2028
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.